Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTR192G + dscCfaE
- Development stage
- Unknown
- Lead developer
- U.S. Army Medical Research and Development Command
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
LTR192G + dscCfaE is an investigational recombinant protein subunit vaccine combination developed by the U.S. Army Medical Research and Development Command (USAMRDC) for the prevention of diarrhea caused by enterotoxigenic *Escherichia coli* (ETEC). The vaccine consists of two primary components: dscCfaE, a donor strand-complemented recombinant protein derived from the CfaE adhesin subunit of CFA/I fimbriae, and LTR192G, a detoxified single-mutant heat-labile enterotoxin (LT) that acts as a potent mucosal adjuvant. The vaccine is designed to elicit antibodies that block the adherence of ETEC to the intestinal epithelium, thereby preventing colonization and subsequent diarrheal disease. It has been evaluated in Phase 2 clinical trials using intradermal administration to assess efficacy against experimental challenge with ETEC strain H10407.
- Other names
- dscCfaE + LTR192G vaccineETEC fimbrial tip adhesin vaccinerecombinant fimbrial adhesin dscCfaE + LT(R192G)
02
Targets
GNASGM1 (GM1 ganglioside)CfaE (Colonization factor antigen I minor subunit CfaE)
Beyond the preview
Go deeper on LTR192G + dscCfaE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTR192G + dscCfaE.